CD274 and neoplasm: Monoclonal antibodies (mAbs) have been used to reduce the immunosuppression of T cells, to increase the effector-to-suppressor cell ratio, and to support the maintenance of an anti-tumour microenvironment by preventing PD-L1 from associating with PD-1 [73, 74].